Public procurement of hepatitis C medicines in Brazil from 2005 to 2015

• Published in: Ciência & saude coletiva 2017-08, Vol.22 (8), p.2527-2538
• Main Authors: Chaves, Gabriela Costa, Castro, Claudia Garcia Serpa Osorio de, Oliveira, Maria Auxiliadora
• Format: Article
• Language: eng ; por ; spa
• Subjects: Antiviral Agents - economics; Brazil; Drug Costs; Health Expenditures - trends; Health Services Accessibility - economics; Hepatitis C - drug therapy; Hepatitis C - economics; Humans; Interferon-alpha - economics; Polyethylene Glycols - economics; Recombinant Proteins - economics
• ISSN: 1413-8123; 1678-4561
• DOI: 10.1590/1413-81232017228.05602017

This paper analyzes the Minister of Health's (MoH) procurement of medicines for hepatitis C from 2005 to 2015. Data sources were the Integrated General Services Administration (SIASG), to estimate annual expenditure for selected medicines of the MoH Clinical Protocols and Therapeutic Guidelines (PCDT) for Hepatitis C. All presentations and strengths recorded on SIASG were included. The unit prices were estimated based on the purchase with the highest volume each year. There was a 159.5 fold increase in expenditure of the selected medicines from 2005 to 2006, because procurement of those medicines became centralized. In 2007 there was 730% increase in spending due to the incorporation of pegainterferons alfa 2a and 2b. In 2012 the purchase of only two new direct-acting antivirals (DAA) accounted for 99% of total annual expenditure. In 2015 the adoption of a new DAA led to an increase of 230% (R$945 million) in MoH spending. The significant increase of MoH expenditure on medicines for hepatitis C from 2005 to 2015 was due to the increase of volumes purchased as well as the incorporation of alfapeginterferon and new DAAs. Ensuring universal access to treatment for hepatitis C will depend on the implementation of strategies that strengthen the MoH's bargaining power in price reduction negotiations with the manufacturers of monopoly medicines.